Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Atoltivimab / Maftivimab / Odesivimab · Inmazeb, REGN3470

Monoclonal antibody · Antagonist of Orthoebolavirus zairense glycoprotein · developed by Regeneron Pharmaceuticals

Approved FDA, Oct 2020
REGN Developer

What is Atoltivimab / Maftivimab / Odesivimab?

Atoltivimab, maftivimab and odesivimab is a combination of three recombinant human IgG1κ monoclonal antibodies that bind the glycoprotein of Orthoebolavirus zairense, inhibiting the virus. It is studied in Ebola virus disease.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Inmazeb, REGN3470, REGN-EB3
Drug type
Monoclonal antibody
Targets
Orthoebolavirus zairense glycoprotein
Mechanism
Antagonist of Orthoebolavirus zairense glycoprotein
Therapy area
Infectious disease
Developer
Regeneron Pharmaceuticals (REGN)
FDA status
Approved as Inmazeb (October 14, 2020), BLA761169 · FDA label
UNII
FJZ07Q63VY

✅ FDA-approved uses

From the indications section of the FDA label (version of Dec 15, 2025). Read the full label for the exact wording, limitations and safety information.

Conditions studied

Ebola Virus Disease

More from Regeneron Pharmaceuticals

Sources

Updated Oct 25, 2026. Something wrong or missing? Report it on the REGN page.

Follow REGN, the company behind Atoltivimab / Maftivimab / Odesivimab

See REGN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

REGN catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.